Skip to main content
. 2020 Dec 8;9(12):2637. doi: 10.3390/cells9122637

Figure 6.

Figure 6

Comparative analysis of cellular pathway modulation between phenanthriplatin and cisplatin treatments in A549 and IMR90 cells. (A) The top 20 enriched GO biological processes for the A549 phenanthriplatin versus A549 cisplatin comparison. (B) The top 20 enriched GO biological processes for the IMR90 phenanthriplatin versus IMR90 cisplatin comparison. (C) The top 20 enriched KEGG pathways for the A549 phenanthriplatin versus A549 cisplatin comparison. (D) The top 20 enriched KEGG pathways for the IMR90 phenanthriplatin versus IMR90 cisplatin comparison. The x-axes show the number of DEGs per GO biological process. Statistical analysis for KEGG pathway analysis is provided in the panels.